The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company maintains a strong liquidity position (Current Ratio 4.67) and trades at a discount to book value (P/B 0.49), these are offset by stagnant revenue growth (-0.30% YoY) and persistent negative profit margins. The catastrophic 5-year price decline of 95.4% suggests a long-term failure to create shareholder value, rendering the current low valuation a likely value trap.